Bronchial thermoforming system
■Bronchial asthma is one of the common chronic diseases that seriously affect people's health. The World Health Organization estimates that about 300 million people worldwide suffer from asthma, and 1.5 billion disability adjusted life years (DALYs) are associated with asthma every year, accounting for 1% of the total burden of diseases in the world.
■ It is estimated that there are about 30 million asthma patients in China, and the asthma mortality rate is 36.7/100000, which is much higher than that in developed countries. According to the data of Beijing asthma epidemiological survey in 2011, compared with 2002, the prevalence rate of adult asthma in urban residents doubled and that in suburban residents increased by 1.5 times, while the asthma control rate was only 34.9%.
■ Due to the aggravation of asthma disease burden, China listed bronchial asthma as one of the key chronic respiratory diseases in 2008, and included it in the respiratory diseases mainly controlled by the "healthy China 2020" prevention and control plan. With the increasing incidence of asthma, severe / refractory asthma is also increasing.
■ About 5% of patients with asthma are severe / refractory asthma. The frequency of emergency treatment and hospitalization are 15 times and 20 times that of mild to moderate asthma respectively. It is the main reason for the increase of asthma treatment cost, disability and death, and it is a difficult problem in asthma treatment. Therefore, improving the diagnosis and treatment level of refractory asthma is of great significance to improve the overall control level and prognosis of asthma and reduce medical costs.
■ It is estimated that there are about 30 million asthma patients in China, and the asthma mortality rate is 36.7/100000, which is much higher than that in developed countries. According to the data of Beijing asthma epidemiological survey in 2011, compared with 2002, the prevalence rate of adult asthma in urban residents doubled and that in suburban residents increased by 1.5 times, while the asthma control rate was only 34.9%.
■ Due to the aggravation of asthma disease burden, China listed bronchial asthma as one of the key chronic respiratory diseases in 2008, and included it in the respiratory diseases mainly controlled by the "healthy China 2020" prevention and control plan. With the increasing incidence of asthma, severe / refractory asthma is also increasing.
■ About 5% of patients with asthma are severe / refractory asthma. The frequency of emergency treatment and hospitalization are 15 times and 20 times that of mild to moderate asthma respectively. It is the main reason for the increase of asthma treatment cost, disability and death, and it is a difficult problem in asthma treatment. Therefore, improving the diagnosis and treatment level of refractory asthma is of great significance to improve the overall control level and prognosis of asthma and reduce medical costs.
